GCM
AMPH icon

Gallacher Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Gallacher Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,971
Closed -$279K – 283
2024
Q2 		$279K Buy
+6,971
New +$289K 0.15% 193
2024
Q1 		– Sell
-5,750
Closed -$356K – 267
2023
Q4 		$356K Buy
+5,750
New +$302K 0.2% 131

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gallacher Capital Management's AMPH Position: Q3 2024 in Review

Gallacher Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2024, closing a stake of 6,971 shares — an estimated $279K sold.

Gallacher Capital Management first reported a position in AMPH in Q4 2023 and held it in 2 quarters. The position peaked at $356K in Q4 2023. 279 funds tracked by Wall St. Rank hold AMPH as of Q3 2024.

  • Gallacher Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Gallacher Capital Management sold 6,971 Amphastar Pharmaceuticals shares in Q3 2024, an estimated $279K.
  • Gallacher Capital Management first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Gallacher Capital Management's Amphastar Pharmaceuticals position peaked at $356K in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2024.

Based on Gallacher Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.